MONTREAL, QUEBEC--(MARKET WIRE)--Nov 6, 2008 -- Theratechnologies (Toronto:TH.TO - News) announced today that new 26-week data from a combined analysis of both its Phase 3 clinical trials testing tesamorelin in HIV-associated lipodystrophy were presented as a poster (Poster Number 19) at the 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, in London, England. The results of the combined Phase 3 trials presented at this HIV-focused workshop indicate that a daily administration of 2 mg of tesamorelin is beneficial in reducing visceral adipose tissue (VAT) in HIV-infected patients regardless of the type of antiretroviral therapy (ART) regimen used to treat the HIV infection.
